ArticleProbiotics and antimicrobial proteins2026
Protective Effects of Double-layered Multinucleated Microcapsules Containing Bifidobacterium adolescentis FS2-3 Against Enteritis Mediated by Different Pathogens.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Bifidobacterium adolescentis (B. adolescentis), a dominant probiotic in the gut of infants and healthy adults, exerts protective effects on immune development and disease prevention. However, the intervention capability of B. adolescentis against different pathogenic bacteria remains unclear. In this study, we verified that B. adolescentis FS2-3 showed inhibitory effects against five common pathogenic bacteria, including Shigella dysenteriae CMCC 51,252, Klebsiella pneumoniae NCTC 13,440, Pseudomonas aeruginosa CMCC 10,104, Salmonella enteritidis CMCC 50,746, and Campylobacter jejuni CICC 22,936. To improve its intestinal colonization efficiency, we constructed double-layered multinucleated microcapsules (probiotic microcapsules) of B. adolescentis FS2-3 and evaluated their effects on bacterial enteritis induced by five representative foodborne pathogens. The in vitro experiments showed that the survival rate of B. adolescentis FS2-3 in the microcapsules was increased by 5.76 times compared with the unencapsulated strain. Additionally, the probiotic microcapsules significantly reduced intestinal tissue damage and inflammation in all enteritis mice, especially in Salmonella-infected mice. Specifically, the probiotic microcapsules reversed the abnormal bacterial composition by promoting the colonization of beneficial bacteria Bifidobacterium, Alloprevotella, and Lachnospiraceae. Furthermore, the probiotic microcapsules inhibited the overexpression of TLR-4 and reduced the expression of inflammatory mediators, including IL-1β, NF-κB, and TNF-α. These findings provide new insights into the application of probiotic microcapsules in the treatment of enteritis.
Indexed as
Identifiers
42560463What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.